{"id":60404,"date":"2024-02-28T06:47:15","date_gmt":"2024-02-28T06:47:15","guid":{"rendered":"https:\/\/medsname.com\/rantac-300\/"},"modified":"2026-05-01T10:49:16","modified_gmt":"2026-05-01T10:49:16","slug":"rantac-300","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/rantac-300\/","title":{"rendered":"Rantac 300"},"content":{"rendered":"

<\/p>\n

\n

⚡ Quick Answer — What is Rantac 300?<\/h3>\n

Rantac 300<\/strong> \u03c0\u03b5\u03c1\u03b9\u03ad\u03c7\u03b5\u03b9 ranitidine 300 mg<\/strong> (made by JB Chemicals) — a histamine H2<\/sub> receptor antagonist that reduces stomach acid. \u03a3\u03b7\u03bc\u03b1\u03bd\u03c4\u03b9\u03ba\u03ae \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03c4\u03b9\u03ba\u03ae \u03c3\u03b7\u03bc\u03b5\u03af\u03c9\u03c3\u03b7:<\/strong> ranitidine was withdrawn from the United States, European Union, United Kingdom, and Canadian markets in 2020<\/strong> after the discovery of N-nitrosodimethylamine (NDMA, a probable human carcinogen) contamination in finished ranitidine products. The Indian regulator (CDSCO) has not formally withdrawn ranitidine, so it remains available in the Indian market. Most major regulators now recommend famotidine<\/strong> (Famocid) as the preferred H2<\/sub>-antagonist substitute. If you live in a country where ranitidine has been withdrawn by your local regulator, please review the warning below before ordering, and consider switching to famotidine. Standard adult dose where ranitidine is still used:<\/strong> 150 mg twice daily, or 300 mg at bedtime, for up to 8 weeks.<\/p>\n<\/div>\n

\n\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong> \u03a0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae\u03c2 WHO-GMP \u00b7 \u0394\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u00b7 \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u00b7 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03b5\u03c2 \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>\n<\/div>\n

\ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n

\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n

\u03a4\u03b1 \u03b3\u03b5\u03bd\u03cc\u03c3\u03b7\u03bc\u03b1 \u03c6\u03ac\u03c1\u03bc\u03b1\u03ba\u03ac \u03bc\u03b1\u03c2 \u03c0\u03c1\u03bf\u03ad\u03c1\u03c7\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ad\u03c2 \u03c0\u03bf\u03c5 \u03c0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd WHO-GMP \u03ba\u03b1\u03b9 \u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03bd\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03bf\u03c3\u03bc\u03af\u03c9\u03c2 \u03c3\u03b5 \u03b4\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae, \u03b1\u03c0\u03bb\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u2014 \u03c7\u03c9\u03c1\u03af\u03c2 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5 \u03c3\u03c4\u03bf \u03b5\u03be\u03c9\u03c4\u03b5\u03c1\u03b9\u03ba\u03cc \u03c4\u03bf\u03c5 \u03b4\u03ad\u03bc\u03b1\u03c4\u03bf\u03c2. \u039f\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u03b4\u03c1\u03bf\u03bc\u03bf\u03bb\u03bf\u03b3\u03bf\u03cd\u03bd\u03c4\u03b1\u03b9 \u03bc\u03ad\u03c3\u03c9 \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf\u03c5 \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae (\u03bf\u03b9 \u03c0\u03b5\u03c1\u03b9\u03b3\u03c1\u03b1\u03c6\u03ad\u03c2 \u03b5\u03ba\u03ba\u03b1\u03b8\u03ac\u03c1\u03b9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03c1\u03b9\u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03bf\u03c5\u03bd \u03c1\u03c5\u03b8\u03bc\u03b9\u03c3\u03bc\u03ad\u03bd\u03bf \u03b5\u03c0\u03b5\u03be\u03b5\u03c1\u03b3\u03b1\u03c3\u03c4\u03ae \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ce\u03bd \u03bc\u03b5 \u03ba\u03ac\u03c1\u03c4\u03b1 \u2014 \u03c0\u03bf\u03c4\u03ad \u201cMedsBase\u201d \u03ae \u03bf\u03c0\u03bf\u03b9\u03bf\u03b4\u03ae\u03c0\u03bf\u03c4\u03b5 \u03cc\u03bd\u03bf\u03bc\u03b1 \u03c6\u03b1\u03c1\u03bc\u03ac\u03ba\u03bf\u03c5). \u0393\u03af\u03bd\u03bf\u03bd\u03c4\u03b1\u03b9 \u03b4\u03b5\u03ba\u03c4\u03ad\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03bb\u03b7\u03c1\u03c9\u03bc\u03ad\u03c2 \u03bc\u03b5 \u03ba\u03c1\u03c5\u03c0\u03c4\u03bf\u03bd\u03bf\u03bc\u03af\u03c3\u03bc\u03b1\u03c4\u03b1 \u03ba\u03b1\u03b9 \u03c4\u03c1\u03b1\u03c0\u03b5\u03b6\u03b9\u03ba\u03ae \u03bc\u03b5\u03c4\u03b1\u03c6\u03bf\u03c1\u03ac SEPA. \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2 \u0395\u03be\u03b1\u03c3\u03c6\u03b1\u03bb\u03af\u03c3\u03b5\u03ce\u03c2 \u03bc\u03b1\u03c2.<\/p>\n

Critical regulatory and safety notice — ranitidine and NDMA contamination.<\/strong> In September 2019, routine drug-quality testing detected N-nitrosodimethylamine (NDMA)<\/strong> — a probable human carcinogen — in finished ranitidine products. Subsequent investigation showed that ranitidine itself is chemically unstable and breaks down into NDMA in storage, particularly with heat and humidity. Levels rose well above the acceptable daily intake threshold. Between April 2020 and August 2020, the FDA, European Medicines Agency, MHRA (UK), and Health Canada<\/strong> all requested removal of ranitidine products from their respective markets. Major manufacturers in the US and EU stopped supply. The Indian regulator CDSCO has not formally withdrawn ranitidine<\/strong>, citing local data; ranitidine therefore remains available in the Indian market and from manufacturers serving that market. The widely-recommended substitute is famotidine<\/strong> — a chemically stable H2<\/sub>-antagonist with the same mechanism, similar efficacy, and no NDMA contamination signal. If you previously used ranitidine, please discuss switching to famotidine (see Famocid<\/a>) with a qualified physician.<\/div>\n

What Rantac 300 Is<\/h2>\n

Rantac 300 is the JB Chemicals brand of ranitidine<\/strong>, an H2<\/sub>-receptor antagonist that was widely used worldwide between the 1980s and 2020 for acid-related disease. Each tablet contains 300 mg of ranitidine. Ranitidine is the second H2<\/sub> antagonist developed (after cimetidine) and was for decades the world’s most widely prescribed prescription medicine. The 2020 NDMA-contamination withdrawal in major markets has shifted clinical practice almost entirely to famotidine.<\/p>\n

How Ranitidine Works (Mechanism)<\/h2>\n

Ranitidine is a competitive, reversible antagonist at the histamine H2<\/sub> receptor on the parietal-cell basolateral membrane. Histamine release from gastric enterochromaffin-like cells is the dominant signal driving acid secretion; blocking this signal reduces acid output by 60–80% at standard doses. Onset within 30 minutes, peak 1–3 hours, duration 8–12 hours. The mechanism is identical to famotidine; the difference between the two molecules is purely chemical — ranitidine’s aminonitrile group makes it prone to forming NDMA in storage, while famotidine’s thiazole structure does not.<\/p>\n

Why Was Ranitidine Withdrawn? (NDMA Story)<\/h2>\n

In June 2019, an independent online pharmacy submitted ranitidine samples for routine NDMA screening (NDMA is a known contaminant of certain blood-pressure medicines and tobacco products) and reported levels far above the FDA’s acceptable daily intake of 96 ng. Subsequent FDA testing confirmed the finding and showed that NDMA levels increased with storage at higher temperatures. By April 2020, the FDA requested removal of all ranitidine products from the US market (this is a stronger action than a recall). The EMA, MHRA, and Health Canada followed within months. The mechanism is now understood: ranitidine’s dimethylamine group can break down to NDMA in the molecule itself or react with nitrites in the stomach to form NDMA in vivo<\/em>. The risk to any individual patient from past ranitidine use is small in absolute terms, but unnecessary exposure to a probable carcinogen when an effective alternative (famotidine) exists is no longer considered acceptable.<\/p>\n

The Indian regulator CDSCO reviewed the data in 2020 and concluded that local ranitidine products met national quality standards, declining to issue a formal withdrawal. Ranitidine therefore remains legally available in the Indian market and from manufacturers serving that market. Customers in countries where ranitidine has been withdrawn by their national regulator should consider switching to famotidine.<\/p>\n

Indications Where Ranitidine Was Used<\/h2>\n

Where ranitidine is still used, the indication list mirrors famotidine:<\/p>\n

    \n
  • Mild-to-moderate GERD — on-demand or short-term<\/li>\n
  • Peptic ulcer disease (duodenal and gastric)<\/li>\n
  • NSAID ulcer prophylaxis (lower-risk patients)<\/li>\n
  • Stress-ulcer prophylaxis (where PPI is not preferred)<\/li>\n
  • Aspiration prophylaxis before surgery<\/li>\n
  • Zollinger-Ellison syndrome — high-dose adjunct<\/li>\n<\/ul>\n

    For each of these indications, famotidine is now the recommended H2<\/sub> antagonist of choice; PPIs are first-line for chronic moderate-to-severe disease.<\/p>\n

    \u03a7\u03bf\u03c1\u03ae\u03b3\u03b7\u03c3\u03b7<\/h2>\n\n\n\n\n\n\n\n\n\n
    Indication \/ patient<\/th>\nAdult dose<\/th>\nDuration \/ notes<\/th>\n<\/tr>\n<\/thead>\n
    GERD — mild-to-moderate<\/td>\n150 mg twice daily, or 300 mg at bedtime<\/td>\n6–12 weeks; review<\/td>\n<\/tr>\n
    Duodenal ulcer healing<\/td>\n300 mg at bedtime, or 150 mg twice daily<\/td>\n4\u20136 \u03b5\u03b2\u03b4\u03bf\u03bc\u03ac\u03b4\u03b5\u03c2<\/td>\n<\/tr>\n
    Gastric ulcer healing<\/td>\n300 mg at bedtime<\/td>\n6–8 weeks<\/td>\n<\/tr>\n
    Maintenance therapy<\/td>\n150 mg at bedtime<\/td>\nas needed<\/td>\n<\/tr>\n
    Renal impairment (CrCl < 50)<\/td>\n150 mg once daily<\/td>\nreduce dose<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

    \u03a0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2<\/h2>\n

    Ranitidine has a comparable side-effect profile to famotidine: headache, dizziness, constipation or diarrhoea, fatigue (1–3%). Uncommon: confusion (especially in elderly or renally impaired), reversible thrombocytopenia, hepatitis, severe hypersensitivity. Unlike cimetidine, ranitidine does not cause significant anti-androgen effects.<\/p>\n

    \u0391\u03bb\u03bb\u03b7\u03bb\u03b5\u03c0\u03b9\u03b4\u03c1\u03ac\u03c3\u03b5\u03b9\u03c2 \u03a6\u03b1\u03c1\u03bc\u03ac\u03ba\u03c9\u03bd<\/h2>\n

    Ranitidine is a much weaker CYP enzyme inhibitor than cimetidine. Main interactions are absorption-related: HIV antiretrovirals that need acid (atazanavir, rilpivirine), antifungals (ketoconazole, itraconazole), iron supplements, and calcium carbonate.<\/p>\n

    \u0391\u03bd\u03c4\u03b5\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2 \u03ba\u03b1\u03b9 \u03c0\u03c1\u03bf\u03c6\u03c5\u03bb\u03ac\u03be\u03b5\u03b9\u03c2<\/h2>\n